Business Description
Harmony Biosciences Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US4131971040
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.83 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.41 | |||||
Debt-to-EBITDA | 0.87 | |||||
Interest Coverage | 8.08 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.64 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.9 | |||||
3-Year EBITDA Growth Rate | 296.2 | |||||
3-Year EPS without NRI Growth Rate | 120.5 | |||||
3-Year Book Growth Rate | 68.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 23.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 19.05 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.32 | |||||
9-Day RSI | 41.2 | |||||
14-Day RSI | 42.55 | |||||
6-1 Month Momentum % | 33.81 | |||||
12-1 Month Momentum % | 1.49 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.75 | |||||
Quick Ratio | 2.72 | |||||
Cash Ratio | 2.16 | |||||
Days Inventory | 14.27 | |||||
Days Sales Outstanding | 39.2 | |||||
Days Payable | 24.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | -0.1 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.17 | |||||
Operating Margin % | 32.99 | |||||
Net Margin % | 22.14 | |||||
FCF Margin % | 37.69 | |||||
ROE % | 28.26 | |||||
ROA % | 17.23 | |||||
ROIC % | 42.21 | |||||
ROC (Joel Greenblatt) % | 18553.83 | |||||
ROCE % | 30.76 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 13.77 | |||||
Forward PE Ratio | 10.84 | |||||
PE Ratio without NRI | 10.74 | |||||
Price-to-Owner-Earnings | 25.07 | |||||
PS Ratio | 2.99 | |||||
PB Ratio | 3.55 | |||||
Price-to-Tangible-Book | 5.02 | |||||
Price-to-Free-Cash-Flow | 8 | |||||
Price-to-Operating-Cash-Flow | 8 | |||||
EV-to-EBIT | 7.76 | |||||
EV-to-EBITDA | 6.91 | |||||
EV-to-Revenue | 2.63 | |||||
EV-to-Forward-Revenue | 2.19 | |||||
EV-to-FCF | 6.98 | |||||
Price-to-Graham-Number | 1.55 | |||||
Price-to-Net-Current-Asset-Value | 15.53 | |||||
Price-to-Net-Cash | 182.44 | |||||
Earnings Yield (Greenblatt) % | 12.89 | |||||
FCF Yield % | 13.24 |